Evidence map›Paper›PMID 41794997›Full record

ArticleCommunications biology2026

OSBPL3 drives colorectal cancer progression via Hippo-YAP signaling and modulates MEK inhibitor sensitivity.

Yuchen Zhong, Chaojing Zheng, Zitong Wang, Weiyuan Zhang, Hongyu Wu, Jun Luo, Hao Zhang, Chunlin Wang, Chenkai Zhang, Hanqing Hu and 4 more

Abstract read
In one paragraph

Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yuchen Zhong *Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou City, Zhejiang Province, China.ORCID http://orcid.org/0000-0002-8643-2052
Chaojing Zheng *Department of Colorectal Cancer Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou City, Zhejiang Province, China.
Zitong Wang *Department of Colorectal Cancer Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin City, Heilongjiang Province, China.
Weiyuan ZhangDepartment of Colorectal Cancer Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin City, Heilongjiang Province, China.
Hongyu WuDepartment of Colorectal Cancer Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou City, Zhejiang Province, China.
Jun LuoDepartment of Colorectal Cancer Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin City, Heilongjiang Province, China.
Hao ZhangDepartment of Colorectal Cancer Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin City, Heilongjiang Province, China.
Chunlin WangDepartment of Colorectal Cancer Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin City, Heilongjiang Province, China.
Chenkai ZhangDepartment of Colorectal Cancer Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin City, Heilongjiang Province, China.ORCID http://orcid.org/0009-0002-4652-0282
Hanqing HuDepartment of Colorectal Cancer Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin City, Heilongjiang Province, China.
Ziming YuanDepartment of Colorectal Cancer Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin City, Heilongjiang Province, China.
Meng WangDepartment of Colorectal Cancer Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou City, Zhejiang Province, China.
Qian ZhangDepartment of Colorectal Cancer Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou City, Zhejiang Province, China. Zhangqian@zjcc.org.cn.ORCID http://orcid.org/0009-0006-8108-5174
Guiyu WangDepartment of Colorectal Cancer Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin City, Heilongjiang Province, China. guiywang@hrbmu.edu.cn.ORCID http://orcid.org/0000-0001-7166-6377

Funding

National Natural Science Foundation of China (National Science Foundation of China) 62276084National Natural Science Foundation of China (National Science Foundation of China) U23A20482
6 · The paper itself

Abstract

Colorectal cancer progression involves dysregulated signaling pathways such as Hippo-YAP, but upstream regulators remain poorly defined. Here we demonstrate that oxysterol-binding protein-like 3 (OSBPL3) modulates Hippo-YAP signaling to drive tumor aggressiveness. Analysis of clinical specimens and experimental models shows that elevated OSBPL3 levels in colorectal cancer tissues correlate with shortened patient survival. Depleting OSBPL3 impairs cancer cell proliferation and invasion and induces cell cycle arrest, while its overexpression accelerates tumor growth. Mechanistic studies reveal that OSBPL3 binds 14-3-3 proteins to promote YAP1 nuclear translocation, activating downstream oncogenic pathways. Notably, tumors with high OSBPL3 expression exhibit resistance to MEK inhibitors, but this resistance is overcome by YAP1 suppression or combined YAP/MEK inhibition in patient-derived organoids. These results establish OSBPL3 as a critical Hippo-YAP pathway regulator and propose targeting OSBPL3-mediated signaling as a therapeutic strategy for colorectal cancers with Hippo pathway alterations.

Indexed as

Adaptor Proteins, Signal TransducingColorectal NeoplasmsProtein Kinase InhibitorsProtein Serine-Threonine KinasesTranscription FactorsAnimalsCell Line, TumorCell ProliferationDisease ProgressionHippo Signaling PathwayHumansMiceOxysterol Binding ProteinsSignal TransductionYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingOSBPL3 protein, humanOxysterol Binding ProteinsProtein Kinase InhibitorsProtein Serine-Threonine KinasesTranscription FactorsYAP1 protein, humanYAP-Signaling Proteins

Identifiers

PMID41794997
PMCPMC13096400

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.